568 reports of this reaction
3.9% of all MICONAZOLE NITRATE reports
#4 most reported adverse reaction
VULVOVAGINAL PRURITUS is the #4 most commonly reported adverse reaction for MICONAZOLE NITRATE, manufactured by H E B. There are 568 FDA adverse event reports linking MICONAZOLE NITRATE to VULVOVAGINAL PRURITUS. This represents approximately 3.9% of all 14,417 adverse event reports for this drug.
Patients taking MICONAZOLE NITRATE who experience vulvovaginal pruritus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VULVOVAGINAL PRURITUS is moderately reported among MICONAZOLE NITRATE users, representing a notable but not dominant share of adverse events.
In addition to vulvovaginal pruritus, the following adverse reactions have been reported for MICONAZOLE NITRATE:
The following drugs have also been linked to vulvovaginal pruritus in FDA adverse event reports:
VULVOVAGINAL PRURITUS has been reported as an adverse event in 568 FDA reports for MICONAZOLE NITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VULVOVAGINAL PRURITUS accounts for approximately 3.9% of all adverse event reports for MICONAZOLE NITRATE, making it a notable side effect.
If you experience vulvovaginal pruritus while taking MICONAZOLE NITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.